Stopping blood thinners after antiphospholipid antibodies disappear
Part of Heart & circulation, Immune system & allergy clinical trials.
This study tests whether it is safe to stop taking blood thinners (vitamin K antagonists) if the antiphospholipid antibodies that caused your condition have been gone for at least a year. If you qualify, stopping treatment might reduce your risk of bleeding and improve your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with antiphospholipid syndrome (a condition that increases blood clot risk) according to standard criteria.
- Your antiphospholipid antibodies (LA, aCL, and aβ2GPI) have been negative in at least two tests taken at least 12 months apart, with at least one negative test within the last 3 months.
- You have been on blood thinners (vitamin K antagonists like warfarin) for more than 12 months.
- You have not had severe blood clots (like massive pulmonary embolism, or clots in the liver, gut, kidneys, or brain), or any arterial clots, or recurrent clots while on blood thinners.
- You are not pregnant or breastfeeding, and you do not have a mechanical heart valve or other condition that requires ongoing blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of blood thinners (vitamin K antagonists) in people with antiphospholipid syndrome, a condition where the immune system attacks healthy cells and increases blood clot risk. The goal is to see if one is better at preventing future blood clots.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
This study tests whether it is safe to stop taking aspirin after getting a CH-VAD heart pump, which helps pump blood for people with advanced heart failure. If you are taking aspirin to prevent blood clots, this trial will help doctors learn if you can stop it.
This Phase 3 trial studies whether it’s safer to avoid long-term blood thinners after a spontaneous brain bleed in people with atrial fibrillation (an irregular heart rhythm). It compares different prevention strategies to lower the risk of stroke or other blood-vessel problems without causing new, serious bleeding.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.